Cephalon is a global biopharmaceutical company dedicated to discovering, developing and bringing to market medications to improve the quality of life of individuals around the world. Since its inception in 1987, Cephalon has brought first-in-class and best-in-class medicines to patients in several therapeutic areas. Cephalon has the distinction of being one of the world's fastest-growing biopharmaceutical companies, now among the Fortune 1000 and a member of the S&P 500 Index, employing approximately 4,000 people worldwide. The company sells numerous branded and generic products around the world. In total, Cephalon sells more than 150 products in nearly 100 countries.

IRLAB is a Swedish drug discovery and development company providing novel treatments for disorders of the brain. IRLAB is engaged in programmes targeting core dysfunctions in Parkinson’s disease and dementias. IRLAB has identified, and is currently engaged in clinical development of, two novel compounds aimed at offering improved clinical benefit for patients with Parkinson’s disease.

Longeviti Neuro Solutions LLC operates as a neuro-technology company that focuses on brain surgery solutions. It offers a platform for novel medical devices. The company was founded by Chad Gordon and Jesse Christopher in 2016 and is headquartered in Hunt Valley, MD.

Hopstem Biotechnology LLC is a company headquartered in Hangzhou, China, that operates as a biotechnology company. The firm was founded in 2017 by Jing Fan, he has been the CEO since the company founding.\nThe company says this about itself: Hopstem Biotechnology is one of the first few iPSC cell therapy companies in China. The company was founded in January 2017 in Hangzhou (China) and Baltimore (US) by neuroscientists and stem-cell biologists from Johns Hopkins University. Hopstem has established a world-leading neural differentiation platform as well as patented iPSC reprogramming method and high standard GMP manufactory and quality system. The mission of Hopstem is to apply these cutting-edge technologies to develop innovative cell therapies for CNS and other disorders. Our leading clinical product, hNPC01, is a human forebrain neural progenitor cell product for stroke and traumatic brain injuries, etc.

Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. They help people with debilitating and complex conditions that are often difficult to diagnose and treat. They are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, they also established ourselves as a leader in the field of multiple sclerosis. In 2016, their focus expanded to include Sanofi’s programs in oncology and immunology. Their approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, they rapidly grew to become one of the world’s leading biotechnology companies, recognized for their pioneering development of treatments for rare genetic disorders and their innovative contributions to medical science and biomanufacturing.

FANCL Corp. engages in the manufacture and sale of cosmetics and nutritional supplements. It operates through the following segments: Cosmetics, Nutritional Supplements, and Others. The Cosmetics segment deals with manufacture and sale of cosmetics and provides original equipment manufacturer products. The Nutritional Supplements segment handles manufacture and sale of food supplements. The Others segment includes online sales of undergarments, health equipment, and lifestyle products. It also offers germinated brown rice, kale juice, and esthetic business. The company was founded by Kenji Ikemori in April 1980 and is headquartered in Yokohama, Japan.

Cephalon France SAS manufactured pharmaceutical products. The firm provided pharmaceutical activities which include development, clinical research and production of active ingredients The company was founded in 1982 and was headquartered in Maisons-Alfort, France

REGENX Biosciences is a biopharmaceutical company that develops therapeutics and research tools based on adeno-associated viral (AAV) vectors. The company offers NAV, a gene delivery technology that includes recombinant adeno-associated viral vectors. Its technology is used for the treatment of metabolic disorders, muscle diseases, hematologic disorders, ocular diseases, and neurodegenerative disorders; and clinical trails in therapeutic areas, such as inherited diseases, CNS disorders, heart failure, and vaccines. The company also offers reagent services for various applications, including molecular therapies, understanding biological activity, and target validation, creating disease models and screening in vivo, and genome-wide association studies. In addition, it offers custom products and services, including AAV plasmids, AAV Vector reporter systems, and custom AAV vectors to the researchers. The company is based in Washington, District Of Columbia.

Takasago International Corp. engages in the manufacture and sale of flavors, fragrances, aroma ingredients, and fine chemicals. It operates through the following regional segments: Japan, America, Europe, and Asia. All of the segments handle flavor, fragrances, and aroma ingredients. The Japan segment also deals with fine chemicals and offer real estate leasing and other services. The America Segment also sells fine chemicals. The company was founded by Nanko Kaisho on February 09, 1920 and is headquartered in Tokyo, Japan.

Anhui Xiaolong Technology Co., Ltd., established on 2018-07-31, Business scope includes medical device research and development;electronic product development;computer software development,Technical Support and Technical Services;system integration;two,Class III Medical Devices,laboratory instrument,electronic product,Sales of medical electronic equipment;Import and export of goods or technology(Goods prohibited by the state or subject to administrative approval and import and export are excluded).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Baya Hospital Investment Management (Shanghai) Co., Ltd., established on 2014-01-28, Business scope includes investment management,Industrial Investment,Investment Advisory,engaged in biotechnology,Technology development in the field of medical technology,technology transfer,technical consulting,Technical Services,computer software development,food circulation,Class I medical device,Sales of computer software and auxiliary equipment,computer system integration,Domestic road freight forwarder,Warehousing Services(In addition to dangerous goods),Engaged in the import and export of goods and technology. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Guangzhou Ruizhen Regenerative Medicine Technology Co., Ltd., established on 2019-01-31, Business scope includes research and development of biological products(Does not include licensed operations);Stem Cell Drug Development;Stem Cell Technology Research,to develop;Biotechnology Consulting,communication service;Biotechnology Development Services;Health Management Consulting Services(Medical treatment activities subject to approval,Except for psychological counseling,Does not include licensed operations,Projects prohibited by laws and regulations shall not be operated);Medical supplies and equipment retail(Does not contain drugs and medical devices);Import and export(Excluding franchised products);Sales of Biological Products(Does not include licensed operations);Sales of biological diagnostic reagents and kits(Does not include license approval items);Manufacture of stem cell series technical engineering products;Sales of stem cell series technical engineering products;Manufacture of stem cell engineering series products;Sales of stem cell engineering series products;Preparation of cell preparations and related products;Sales of cell preparations and related products;Stem Cell Biotechnology Consulting Services;Stem Cell Biotechnology Transfer Services;Stem Cell Biotechnology Services;collection of stem cells,storage,preparation service(Without umbilical cord blood hematopoietic stem cell collection,storage);Genetic testing and disease screening services;Collection of immune cells,storage,preparation service(Without umbilical cord blood hematopoietic stem cell collection,storage);Technology development of stem cell engineering series products;Research and development of stem cell series technical engineering products

Pfizer Inc. (NYSE: PFE, /ˈfaɪzər/) is an American multinational pharmaceutical corporation headquartered in New York City was founded in 1849, based in New York City and was listed on New York Stock Exchange. It is one of the world's largest pharmaceutical companies. It is listed on the New York Stock Exchange, and its shares have been a component of the Dow Jones Industrial Average since 2004. Pfizer ranked No. 57 on the 2018 Fortune 500 list of the largest United States corporations by total revenue.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Shenzhen Fuerkang Trading Co., Ltd., established on 2003-07-14, Business scope includes general business items:air purification equipment,Fresh air ventilation and environmental protection equipment,Fire fighting equipment and pipes,Air Conditioning Dehumidification Humidification Heating Heating Equipment,Water purification and energy saving products and technologies,Intelligent control equipment and automated logistics system,cleaning supplies,electronic product,Electronic and electrical equipment,communication equipment,Instrumentation,computer,Technical development of software and auxiliary equipment;Computer System Integration Services;Sales of security technology and protection products and security engineering design;Network technology development,Transfer of own technological achievements,technical consulting;software development;Sales of machinery and equipment;Technical development of medical devices and software systems,Sales,Home installation,debugging,After-sales maintenance and other supporting services;Cleaning Services;Sales and installation of building decoration materials;Packaging Materials,paper products(no publications),Plastic Plastic Products,Photoelectric products,Technology development and sales of new energy products;Labor protection supplies,Anti-static radiation protection products,Rubber floor raised floor,Wholesale of office supplies and office furniture,retail;Domestic Trade,Engaged in the import and export of goods and technology(law,Administrative regulations,Except for items that are subject to approval prior to registration by decision of the State Council).(Business operations involving administrative licensing,Must obtain administrative license documents before operating),The licensing program is:air purification equipment,Fresh air ventilation and environmental protection equipment and pipes,Air conditioning dehumidification heating heating equipment,Technology of water purification and energy saving products,Intelligent control equipment and automated logistics system,cleaning supplies,Electronic and electrical equipment,Instrumentation,Computer Equipment and Systems,money counter,Production of medical devices and software systems.

Manufactures and sells pharmaceuticals

Riken Corp. engages in the manufacture and sale of engine and vehicular components. It operates through the Automotive and Machinery Parts, and Others segments. The Automotive and Machinery Parts segment deals with the company's core products such as piston rings, camshafts, seal rings for transmissions, high-grade cast iron products, and valve lifters. The Others segment includes plumbing equipment business, Electromagnetic Compatibility (EMC) business, and thermal engineering business, The company was founded by Masatoshi Okochi in November 1927 and is headquartered in Tokyo, Japan.